Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01534208 · ClinicalTrials.gov registry record · Phase 3
Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism
A Phase 3 study, sponsored by Repros Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 499
- Enrollment target
NCT01534208 is a Phase 3 study that has completed, run by Repros Therapeutics. The registered enrollment target is 499 participants.
The verdict
NCT01534208, a Phase 3 study, has completed, sponsored by Repros Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 499 participants
- Enrollment target
Study Summary
ZA-300 is meant to determine the safety profile of Androxal (enclomiphene citrate) in men with secondary hypogonadism.
Interventions
- DRUG Androxal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 499 participants |
| Start Date | 2012-05 |
| Est. Completion | 2013-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01534208
The ClinicalTrials.gov registry entry for NCT01534208 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 499 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Repros Therapeutics, which has 50 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Androxal is the first listed.
NCT01534208 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01534208 about?
NCT01534208 is a clinical study titled "Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism". ZA-300 is meant to determine the safety profile of Androxal (enclomiphene citrate) in men with secondary hypogonadism.
What is the current status of trial NCT01534208?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 499 participants. The study started on 2012-05. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01534208?
The interventions under investigation include: Androxal (DRUG).
Who is sponsoring clinical trial NCT01534208?
This trial is sponsored by Repros Therapeutics, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.